Status:

COMPLETED

Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta

Lead Sponsor:

Oregon Health and Science University

Collaborating Sponsors:

Eli Lilly and Company

Osteogenesis Imperfecta Foundation

Conditions:

Osteogenesis Imperfecta

Eligibility:

All Genders

18-85 years

Phase:

PHASE4

Brief Summary

The purpose of this study is to determine the effectiveness of teriparatide (FORTEO), which is human parathyroid hormone 1-34, for increasing bone mass and improving bone structure in adults affected ...

Detailed Description

The purpose of this study is to determine the effectiveness of teriparatide (FORTEO), which is human parathyroid hormone 1-34, for increasing bone mass and improving bone structure in adults affected ...

Eligibility Criteria

Inclusion

  • Previous established diagnosis of Osteogenesis Imperfecta AND
  • \> 2 previous adult fractures, AND/OR
  • BMD at lumbar spine, femoral neck or total hip T score \< -2.0

Exclusion

  • Open epiphyses.
  • History of external beam radiation to the skeleton.
  • Pagets disease.
  • Bone metastases or skeletal malignancies.
  • Total lifetime exposure to any antiresorptive medication \< 90 days (Primary Inclusion).
  • Treatment with any antiresorptive medication 12 months proceeding enrollment - (Secondary Inclusion).
  • Women with OI who are pregnant or unwilling to use 1 form of contraception.
  • Vitamin D insufficiency (25-hydroxyvitamin D \<15ng/ml)

Key Trial Info

Start Date :

June 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 1 2011

Estimated Enrollment :

79 Patients enrolled

Trial Details

Trial ID

NCT00131469

Start Date

June 1 2005

End Date

January 1 2011

Last Update

April 24 2019

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Kennedy Krieger Institute

Baltimore, Maryland, United States, 21205

2

Oregon Health & Science University

Portland, Oregon, United States, 97239-3098

3

Baylor College of Medicine, Department of Molecular and Human Gentics

Houston, Texas, United States, 77030